Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013


Phase I & IIA clinical trials

27 Feb 2013 - 28 Feb 2013 - London, UK



Bookmark and Share


The Phase I & IIa Clinical Trials conference has been revamped for 2013 to provide you with two highly focused and high quality streams, providing answers to the latest questions in early phase drug development. This year we will be looking at how we can design more effective and efficient Phase I & IIa clinical trials, benchmarking against current industry models to find out what works best and how we can adapt this to our trials going forward.

6 Reasons why you MUST attend this conference……

Over 160 attendees from small, medium and large pharma and biotech companies 

Wine Casino networking event - your opportunity to meet new faces in early phase clinical development 

8 interactive sessions: Don’t miss our regulatory Q&A to get the latest updates on EU and US regulations and find out how you can remain compliant 

70 speakers including 6 Vice Presidents, 10 Heads and 15 Directors from pharma and 10 CEOs and CMOs from biotech 

Increased focus on biotech  - with speakers from 13 leading biotech companies 

2 re-engineered streams including one stream entirely dedicated to outsourcing and patient recruitment in early phase trials 

Please quote CQ4170TN when booking your place.

For more information and to download the conference brochure, please visit: 

http://www.informa-ls.com/CQ4170TN




Further information
Scientific News
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!